Mark Wickens

6k citations
12 papers · 5.1k · 3 hit papers · h-index 11

Impact in

  • Oncology top 1%
    • PARP inhibition in cancer therapy
    • Breast Cancer Treatment Studies
    • Cancer Genomics and Diagnostics

Papers in

Mark Wickens

12 papers receiving 4.9k citations

Mark Wickens's Hit Papers

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial 2010 · 2k citations
2k0+6+13Years since publication5001k1.5k

Peers

Mark Wickens
Comparison fields: 5 of 87
  • Oncology 1.9k
  • Cancer Research 691
  • Cardiology and Cardiovascular Medicine 1.1k
  • Genetics 815
  • Reproductive Medicine 285
Replace Sabine Zöchbauer‐Müller with:
Sabine Zöchbauer‐Müller Austria
Enrico Ricevuto Italy
Mariano Monzó Spain
Volkmar Henschel Germany
Richard Piekarz United States
Roshan Agarwal United Kingdom
Iain R. Macpherson United Kingdom
Zsuzsanna Kahán Hungary
Kim Marie Hirshfield United States
Wolfgang J. Köstler Austria
Mark Wickens relative to Sabine Zöchbauer‐Müller Austria Sabine Zöchbauer‐Müller's profile →
Citations per field
00.5×2×4×5.7×
Sabine Zöchbauer‐Müller · 1×
Citations per year

Countries citing papers authored by Mark Wickens

Since Specialization
Citations

This map shows the geographic impact of Mark Wickens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Wickens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Wickens more than expected).

Fields of papers citing papers by Mark Wickens

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Wickens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Wickens. The network helps show where Mark Wickens may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark Wickens, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Wickens Line = papers co-authored together Mark Wickens links everyone, so they are left out of the graph.

All Works

12 of 12 papers shown
#Work
1
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
Hit paper breakdown →
20101955
2
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Hit paper breakdown →
20101453
3
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin
Hit paper breakdown →
2006618
4 2011408
5 2007407
6 1995106
7 200951
8 200034
9 201032
10
Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in subjects with renal impairment.
200126
11 200622
12 20071

About Mark Wickens

Mark Wickens is a scholar working on Oncology, Cardiology and Cardiovascular Medicine, Anesthesiology and Pain Medicine, Pharmacology and Pharmacology, having authored 12 papers that have together received 5.1k indexed citations. Recurring topics across this work include PARP inhibition in cancer therapy (3 papers), Antiplatelet Therapy and Cardiovascular Diseases (3 papers), Anesthesia and Pain Management (2 papers), Pharmacogenetics and Drug Metabolism (1 paper), Alcohol Consumption and Health Effects (1 paper), Pharmacology and Obesity Treatment (1 paper), Heart Failure Treatment and Management (1 paper) and Substance Abuse Treatment and Outcomes (1 paper). The work is most often cited by research in Oncology (1.9k citations), Cancer Research (691 citations), Cardiology and Cardiovascular Medicine (1.1k citations), Genetics (815 citations) and Reproductive Medicine (285 citations). Mark Wickens has collaborated with scholars based in United Kingdom, United States and Sweden. Frequent co-authors include James Carmichael, Michael Leonard Friedlander, Rita Katharina Schmutzler, M. William Audeh, Andrew N.J. Tutt, Jeffrey N. Weitzel, Ursula A. Matulonis, Katherine M. Bell‐McGuinn, Steen Husted and Håkan Emanuelsson. Their work appears in journals such as The Lancet, European Heart Journal, Platelets, British Journal of Clinical Pharmacology and Journal of the American College of Cardiology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact